Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Intracellular Movement of Viruses and Bacteria01:10

Intracellular Movement of Viruses and Bacteria

3.7K
Intracellular bacteria and viruses often comprise a group of highly infectious pathogens that can cause several diseases. Bacterial pathogens include those belonging to the genus Rickettsia responsible for conditions such as rocky mountain spotted fever and the Mediterranean spotted fever; Chlamydia, a genus responsible for a sexually transmitted disease; Coxiella burnetii, an agent responsible for Q fever. Viral pathogens include vaccinia—a poxvirus, and herpes simplex virus—a...
3.7K
Pinching-off of Coated Vesicles01:32

Pinching-off of Coated Vesicles

4.3K
Vesicle budding is orchestrated by distinct cytosolic proteins such as adaptor proteins, coat proteins, and GTPases. To initiate vesicle budding, membrane-bending proteins containing crescent-shaped BAR domains bind to the lipid heads in the bilayer and distort the membrane to form a protein-coated vesicle bud. Adaptors proteins such as AP2 for clathrin-coated vesicles can nucleate on the deformed membrane. Finally, coat proteins such as clathrin or COPI and COPII assemble into a coat forming...
4.3K
Intralumenal Vesicles and Multivesicular Bodies01:38

Intralumenal Vesicles and Multivesicular Bodies

5.0K
Intraluminal vesicles (ILVs) are small vesicles 50-80 nm in diameter formed during the maturation of early endosomes. A specialized endosome containing numerous ILVs is called a multivesicular body (MVB). ILVs contain internalized molecules such as antigens, nucleic acids, proteins, and metabolites. Some of these molecules are released from the MVBs inside exosomes and are transported to other cells. Other MVBs contain molecules that are retained in the ILVs and are later degraded within the...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CCHFV GP38 and GP85 interact with cell-surface glycosaminoglycans.

Npj viruses·2026
Same author

Lassa and Mopeia viruses produce different RIG-I-activating RNA in the absence of a functional viral exoribonuclease domain.

Journal of virology·2026
Same author

[Lyon, at the center of the global virology research challenge].

Virologie (Montrouge, France)·2025
Same author

Development of nebulized inhalation delivery for fusion-inhibitory lipopeptides to protect non-human primates against Nipah-Bangladesh infection.

Antiviral research·2025
Same author

Intranasally administrated fusion-inhibitory lipopeptides block SARS-CoV-2 infection in mice and enable long-term protective immunity.

Communications biology·2025
Same author

Targeting n-myristoyltransferases promotes a pan-Mammarenavirus inhibition through the degradation of the Z matrix protein.

PLoS pathogens·2024

Related Experiment Video

Updated: Mar 1, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.1K

Modeling Ebolavirus Budding with Virus Like Particles.

Olivier Reynard1, Mathieu Mateo2,3

  • 1INSERM U1111-CNRS UMR5308, Centre International de Recherche en Infectiologie (CIRI), Université Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon, Lyon, France. olivier.reynard@inserm.fr.

Methods in Molecular Biology (Clifton, N.J.)
|June 3, 2017
PubMed
Summary

Ebola virus-like particles (VLPs) are produced using VP40 protein in mammalian cells. These VLPs are crucial tools for studying virus budding and are being explored as potential vaccines for Ebola virus disease.

Keywords:
EbolaEbolavirusVP40Viruslike particles

More Related Videos

Sample Preparation for Single Virion Atomic Force Microscopy and Super-resolution Fluorescence Imaging
05:31

Sample Preparation for Single Virion Atomic Force Microscopy and Super-resolution Fluorescence Imaging

Published on: January 2, 2014

10.1K
Simple and Robust in vivo and in vitro Approach for Studying Virus Assembly
09:47

Simple and Robust in vivo and in vitro Approach for Studying Virus Assembly

Published on: March 1, 2012

12.7K

Related Experiment Videos

Last Updated: Mar 1, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.1K
Sample Preparation for Single Virion Atomic Force Microscopy and Super-resolution Fluorescence Imaging
05:31

Sample Preparation for Single Virion Atomic Force Microscopy and Super-resolution Fluorescence Imaging

Published on: January 2, 2014

10.1K
Simple and Robust in vivo and in vitro Approach for Studying Virus Assembly
09:47

Simple and Robust in vivo and in vitro Approach for Studying Virus Assembly

Published on: March 1, 2012

12.7K

Area of Science:

  • Virology
  • Molecular Biology
  • Biochemistry

Background:

  • Virus-like particles (VLPs) are structural analogs of viruses, lacking genetic material.
  • Ebola virus VP40 protein is essential for viral particle assembly and release.
  • VLPs have emerged as valuable tools in virology research and vaccine development.

Purpose of the Study:

  • To describe established protocols for producing and analyzing Ebola virus-like particles (VLPs).
  • To highlight the utility of VLPs in dissecting viral budding mechanisms and identifying key viral proteins.
  • To underscore the potential of VLPs as vaccine candidates against Ebola virus disease.

Main Methods:

  • Expression of Ebola virus VP40 protein in mammalian cell culture systems.
  • Purification and characterization of released VLPs.
  • Analysis of VLP release mechanisms and identification of critical VP40 residues.

Main Results:

  • Demonstrated routine production of Ebola virus-like particles (VLPs).
  • Facilitated detailed studies of the Ebola virus budding process.
  • Identified specific VP40 residues crucial for VLP formation and release.

Conclusions:

  • Protocols for Ebola virus VLP production and analysis are well-established.
  • VLPs serve as indispensable tools for understanding Ebola virus egress.
  • Ebola virus VLPs hold promise as candidates for effective vaccines.